JPH04120020A - Lipid metabolism regulation agent - Google Patents
Lipid metabolism regulation agentInfo
- Publication number
- JPH04120020A JPH04120020A JP2240961A JP24096190A JPH04120020A JP H04120020 A JPH04120020 A JP H04120020A JP 2240961 A JP2240961 A JP 2240961A JP 24096190 A JP24096190 A JP 24096190A JP H04120020 A JPH04120020 A JP H04120020A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- regulating
- lipid metabolism
- threonine
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037356 lipid metabolism Effects 0.000 title claims abstract description 22
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004473 Threonine Substances 0.000 claims abstract description 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 210000002468 fat body Anatomy 0.000 claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 230000004060 metabolic process Effects 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 15
- 239000000243 solution Substances 0.000 abstract description 10
- 239000000843 powder Substances 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 239000002253 acid Substances 0.000 abstract description 3
- 239000012153 distilled water Substances 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000001256 tonic effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000050 nutritive effect Effects 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 19
- 229930195729 fatty acid Natural products 0.000 description 19
- 239000000194 fatty acid Substances 0.000 description 19
- 150000004665 fatty acids Chemical class 0.000 description 19
- 229960002429 proline Drugs 0.000 description 19
- 229960002898 threonine Drugs 0.000 description 13
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- 230000009182 swimming Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- -1 troches Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
この発明はプロリン及び／又はスレオニンを有効成分と
する脂質代謝調節剤に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a lipid metabolism regulator containing proline and/or threonine as active ingredients.
（従来の技術及び発明の解決しようとする課題）従来、
スズメバチの幼虫に関する報告、特に幼虫が分泌するだ
液に関する報告はほとんどなく、その組成は全く解明さ
れていなかった。またスズメバチの驚異的な筋持続力は
どの様な栄養に由来するのかも全く不明であった。(Prior art and problems to be solved by the invention) Conventionally,
There have been very few reports on wasp larvae, especially on the saliva secreted by the larvae, and its composition has not been fully elucidated. It was also unclear what kind of nutrition was responsible for the wasp's amazing muscle endurance.
本発明者らは、種々のスズメバチの幼虫が分泌するだ液
について研究し、その組成を明らかにするとともに、そ
の組成物が極めて有効な筋持続剤として作用することを
見出し、その有効成分を解明して来た。そして、該組成
物が通常のタンパク質あるいはその氷解物中に比較的多
量に含有されるアスパラギン酸やグルタミン酸をほとん
ど含有せず、プロリンとグリシンを主成分とするアミノ
酸組成物であり、脂質代謝調節作用を有することを見出
した。The present inventors studied the saliva secreted by various wasp larvae, clarified its composition, discovered that the composition acts as an extremely effective muscle sustaining agent, and elucidated its active ingredients. I came. The composition contains almost no aspartic acid or glutamic acid, which are contained in relatively large amounts in ordinary proteins or their melted products, and is an amino acid composition mainly composed of proline and glycine, and has a lipid metabolism regulating effect. It was found that
本発明者ちは、上記のアミノ酸組成物の構成成分のうち
、特にプロリンとスレオニンが脂質代謝調節作用を有す
ることを見出し、本発明を完成したものである。The present inventors have completed the present invention by discovering that among the constituent components of the above amino acid composition, proline and threonine in particular have a lipid metabolism regulating effect.
（課題を解決するための手段）
すなわち、本発明はプロリン及び／又はスレオニンを有
効成分として含むことを特徴とする脂質代謝調節剤を提
供することを目的とする。(Means for Solving the Problems) That is, an object of the present invention is to provide a lipid metabolism regulator characterized by containing proline and/or threonine as an active ingredient.
本発明の脂質代謝調節剤に含まれるプロＩＪン、スレオ
ニンはそれぞれＬ−プロリン、Ｌ−スレオニンであるこ
とが好ましい。Preferably, pro-IJ and threonine contained in the lipid metabolism regulator of the present invention are L-proline and L-threonine, respectively.
本発明の脂質代謝調節剤を製造するにあたっては、市販
のプロリン、スレオニンを使用すればよく、両者を任意
の割合で混合して用いてもよい。In producing the lipid metabolism regulator of the present invention, commercially available proline and threonine may be used, or both may be mixed in any proportion.
通常は粉末状で製造すればよいが、混合物とする場合に
は、両者を粉末状態で混合するか、プロＩＪン及びスレ
オニンを蒸留水に溶解し、若しくは両者の溶液を混合し
た後に、水分を留去して製造しても良い。本発明の脂質
代謝調節剤は室温以下で製造することが好ましい。Normally, it can be produced in powder form, but when making a mixture, either the two are mixed in powder form, or pro-IJ and threonine are dissolved in distilled water, or a solution of both is mixed and then water is removed. It may be produced by distillation. The lipid metabolism regulator of the present invention is preferably produced at room temperature or below.
本発明のだ脂質代謝調節剤はマウスに経口投与した場合
に２０ｇ／ｋｇでも全く毒性を発現せず、ＬＤｓｏは２
０ｇ／ｋｇをはるかに上まわる。When the lipid metabolism regulator of the present invention is orally administered to mice, it does not exhibit any toxicity even at 20 g/kg, and the LDso is 2.
Much higher than 0g/kg.
本発明の脂質代謝調節剤は、血中遊離脂肪酸調節剤、肝
臓脂肪代謝調節剤、及び脂肪体脂肪代謝調節剤等の医薬
、及び飲料等の食品として有用である。医薬として用い
る場合の投与形態は特に限定されないが、経口投与、直
腸投与、注射、若しくは輸液による投与等の一般的投与
経路を経ることができる。経口投与の場合には、医薬上
許容される担体、賦形剤、希釈剤等とともに混合し、散
剤、顆粒剤、錠剤、カプセル剤、トローチ剤、シロップ
剤等として用いてもよい。固体散剤、錠剤では吸収に時
間がかかる場合もあるので、適当な添加剤、例えば塩化
す） ＩＪウム等の塩類、ｐＨ調節剤、キレート剤等を
添加して水溶液として投与することが好ましい。本発明
の脂質代謝調節剤には他のアミノ酸、水溶性ビタミン類
、クエン酸等の酸類を添加してもよく、また、適当な風
味を加えてドリンク剤、例えば清涼飲料、粉末飲料、滋
養強壮、栄養補給を目的とした医薬品としての飲料とし
てもよい。また、注射剤としては、適当な緩衝剤、等張
剤等を添加し、滅菌蒸留水に溶解したものを用いて、例
えば静脈内に点滴静注すればよい。The lipid metabolism regulator of the present invention is useful as a medicine such as a blood free fatty acid regulator, a liver fat metabolism regulator, and a fat body fat metabolism regulator, and as a food product such as a drink. When used as a medicine, the administration form is not particularly limited, but common administration routes such as oral administration, rectal administration, injection, or administration by infusion can be used. In the case of oral administration, it may be mixed with pharmaceutically acceptable carriers, excipients, diluents, etc., and used as powders, granules, tablets, capsules, troches, syrups, etc. Since solid powders and tablets may take time to absorb, it is preferable to add appropriate additives, such as salts such as chloride, pH adjusters, chelating agents, etc., and administer as an aqueous solution. Other amino acids, water-soluble vitamins, acids such as citric acid may be added to the lipid metabolism regulator of the present invention, and suitable flavors may be added to make drinks such as soft drinks, powdered drinks, and nutritious tonics. It may also be used as a drink as a medicine for the purpose of nutritional supplementation. Further, as an injection, a solution dissolved in sterile distilled water with addition of an appropriate buffering agent, isotonic agent, etc. may be used, and the solution may be injected intravenously, for example.
本発明の脂質代謝調節剤はきわめて低毒性であるのでそ
の投与量は非常に広範に設定でき、さらに、投与方法、
使用目的により異なるが通常１回に０５〜５ｇ、好まし
くは１回に１〜２ｇ１１日投与量として１〜２０ｇ、好
ましくは４〜１０ｇとすることが好ましい。これらの溶
液剤とする場合には０．５〜１０ｗｔ％溶液として１０
〜１０００ｄ、好ましくは１〜４ｗｔ％溶液として１０
０〜４００社を１回投与量とすればよい。注射剤として
は０．５〜２ｗｔ％溶液として１回あたり１０〜５００
証、好ましくは１００〜３００ｍｆを投与すればよい。Since the lipid metabolism regulator of the present invention has extremely low toxicity, its dosage can be set over a wide range.
Although it varies depending on the purpose of use, it is usually 05 to 5 g at a time, preferably 1 to 2 g at a time, and the daily dosage is preferably 1 to 20 g, preferably 4 to 10 g. When making these solutions, 10% as a 0.5-10wt% solution.
~1000d, preferably 1000d as a 1-4 wt% solution
One dose may be 0 to 400 companies. As an injection, the dosage is 10 to 500 per dose as a 0.5 to 2 wt% solution.
evidence, preferably 100 to 300 mf.
実施例
プロリン及びスレオニンについて、脂質代謝調節作用を
試験した。Example Proline and threonine were tested for their ability to regulate lipid metabolism.
実験方法
（１）血中遊離脂肪酸の定量
■ 検体としてそれぞれ２％のプロＩＪン、グリシン、
スレオニン、ロイシン、セリン、及び２０％グルコース
をｇ体重光たり３７．５μβ投与したマウス（６週令）
に、６０分間の強制負荷遊泳（０，３ｇの負荷）後、直
ちにエーテルにより麻酔を施し、開腹、腹部大静脈から
採血を行った。Experimental method (1) Quantification of free fatty acids in blood ■ Samples were 2% pro-IJ, glycine,
Mice (6 weeks old) administered threonine, leucine, serine, and 20% glucose at 37.5 μβ per g body weight
After forced swimming for 60 minutes (load of 0.3 g), the animals were immediately anesthetized with ether, opened the abdomen, and collected blood from the abdominal vena cava.
■ 採血した血液は遠心分離を行い、血球成分を除いた
。■ The collected blood was centrifuged to remove blood cell components.
■ 遠心分離後の上清について脂肪酸定量を常法に基づ
き、和光純薬工業社製の臨床試薬にて行った。脂肪酸の
定量はアシル−ＣＯＡ合成酵素とアシル−ＣｏＡオキシ
ダーゼの作用により生じた過酸化水素を、ペルオキシダ
ーゼと反応させ、エチル−Ｎ−アニリンと４−アミノア
ンピリンを呈色させたものを５５０ｎｍで吸光度を測定
した。■ Fatty acid quantification was performed on the supernatant after centrifugation using a clinical reagent manufactured by Wako Pure Chemical Industries, Ltd. based on a conventional method. To quantify fatty acids, hydrogen peroxide generated by the action of acyl-COA synthetase and acyl-CoA oxidase is reacted with peroxidase, and ethyl-N-aniline and 4-aminoampyline are colored, which is measured by absorbance at 550 nm. was measured.
反応式
ＡＣ８
ＲＣＤ［ｌＨ”ＡＴＰ↓ＣｏＡ −
ｃｙｌ
ＣｏＡ＋ＡＭＰ＋ＰＰｉ
ｈ３
（２）脂肪体からの遊離脂肪酸の定量
・ラットの脂肪体（Ｆａｔ ｂｏｄｙ）・緩衝液（０，
５Ｍ ＮａＰＢ ｐ８７．５６ ：Ｒｉｎｇｅｒ液＝
９ ： １）
・アルブミン（ＢＳＡ）溶液（１００ｍｇ／１ｆｆ）μ
β
・１＋ｒ＋Ｍ ＣａＣ１２（最終濃度）２００ μ
に
５０ μ！
これにプロリンとアドレナリンを加えて３７℃で反応を
行い、１５．３０，６０そして１２０分後の遊離脂肪酸
を測定した。用いた脂肪体はウィスター系ラット （６
週令）１８０〜２００ｇから摘出した。Reaction formula AC8 RCD[lH”ATP↓CoA - cyl CoA+AMP+PPi h3 (2) Quantification of free fatty acids from fat body・Rat fat body・Buffer solution (0,
5M NaPB p87.56: Ringer's solution =
9: 1) ・Albumin (BSA) solution (100mg/1ff)μ
β ・1+r+M CaC12 (final concentration) 200 μ
50μ! Proline and adrenaline were added to this and the reaction was carried out at 37°C, and free fatty acids were measured after 15, 30, 60 and 120 minutes. The fat body used was that of Wistar rats (6
180 to 200 g (weeks old).
（３）肝臓からの遊離脂肪酸の測定
十分に瀉血したラット肝ｆｉ（ウィスター系、１８０〜
２００ｇ）をスライスし、クレプス−リンガ−液に４０
％ラット血清あるいは４０ｍｇ／ｍｆのＢＳＡを加え、
これに２ｍｇ／ｍｊｌ！になるようプロリンを加え、３
７℃で反応を行い経時的に変化する遊離脂肪酸の量を測
定した。(3) Measurement of free fatty acids from the liver Thoroughly exsanguinated rat liver fi (Wistar series, 180~
Slice 200g) and add 40g to Krebs-Ringer solution.
% rat serum or 40 mg/mf BSA,
2mg/mjl for this! Add proline so that 3
The reaction was carried out at 7°C, and the amount of free fatty acid that changed over time was measured.
結果
（１）血液中の脂肪酸値の変化
プロリン及びスレオニンが脂質代謝調節に及ぼす作用を
明らかにすべく、投与後静置、強制負荷遊泳後の脂肪酸
値を測定した。Results (1) Changes in fatty acid levels in blood In order to clarify the effects of proline and threonine on lipid metabolism regulation, fatty acid levels were measured after administration and after forced stress swimming.
水投与群のコントロールは６０分静置では０，８７ｍＢ
ｑ／Ｉ！、６０分遊泳では１．５５ ｍＥｑ／ Ｉ！と
なった。プロリン投与群の脂肪酸値は６０分静置では０
．８７ ｍＥｑ／Ａ’、 ６０分遊泳では１．７６ ｍ
Ｅｑ／ ｊ！、グリシン投与群では６０分静置で０．９
０ ｍＥｑ／ Ｒ１６０分遊泳では１．３９ ｍＥｑ／
ｉ、スレオニン投与群では６０分静置で０．７２ ｍ
Ｅｑ／ Ｒ１６０分遊泳では１．７０ ｍＥｑ／Ｃロイ
シン投与群では６０分静置で０．８４ ｍＥｑ／ Ｒ１
６０分遊泳では１．４６ｍＥｑ／ｆ、セリン投与群では
６０分静置で０．８３ｍＥｑ／Ｉ２．６０分遊泳では１
．４３ ｍＥｑ／βとなった。２０％グルコース投与群
は６０分静置では０、６４ ｍＥｑ／ｊ！、６０分遊泳
では１．０’ ５ ｍＥｑ／ １２となった。プロリン
及びスレオニン投与群において、コントロールより優位
に脂肪酸を遊離した（第１図）。The control in the water administration group was 0.87 mB after standing for 60 minutes.
q/I! , 1.55 mEq/I for 60 minutes swimming! It became. The fatty acid value in the proline administration group was 0 after standing for 60 minutes.
．． 87 mEq/A', 1.76 m for 60 minutes swimming
Eq/j! , in the glycine administration group, 0.9 after standing for 60 minutes.
0 mEq/ R1.39 mEq/ for 160 minute swim
i. In the threonine administration group, the height was 0.72 m after standing for 60 minutes.
Eq/R1: 1.70 mEq/C for 60 minutes of swimming; 0.84 mEq/R1 for 60 minutes of standing in the leucine-administered group.
1.46 mEq/f for 60 minutes swimming, 0.83 mEq/I for 60 minutes in the serine administration group, 2.1 for 60 minutes swimming.
．． The result was 43 mEq/β. The 20% glucose administration group had 0.64 mEq/j after 60 minutes of standing! , after 60 minutes swimming, it was 1.0'5 mEq/12. In the proline and threonine administration group, fatty acids were released more significantly than in the control (Figure 1).
（２）脂肪体からの脂肪酸の遊離
従来、アドレナリンは脂肪体中のアドレナリン感受性リ
パーゼを活性化し脂肪を分解し、脂肪酸を遊離すること
が知られているが本実験においても同様の結果が得られ
た（第２図）。同じ条件下でアドレナリンの代わりにプ
ロリンを反応させたところ、コントロールよりも高い、
しかしアドレナリンよりも低い脂肪酸の遊離がみられた
（第２図）。これらの結果はプロＩＪンが脂肪体から脂
肪酸を遊離させる作用を有することを示している。(2) Release of fatty acids from fat bodies It has been known that adrenaline activates adrenaline-sensitive lipase in fat bodies, breaks down fat, and releases fatty acids. Similar results were obtained in this experiment. (Figure 2). When we reacted proline instead of adrenaline under the same conditions, it was higher than the control.
However, lower fatty acid release than adrenaline was observed (Figure 2). These results indicate that pro-IJ has the effect of liberating fatty acids from fat bodies.
（３）肝臓から脂肪酸の遊離
プロＩＪンが血中の遊離脂肪酸値を高める作用を示した
ので、肝臓についても脂肪酸の遊離を測定した。肝臓の
スライスをＢＳＡを主成分とするメディウムでプロリン
添加による脂肪酸の遊離をみたところ、経時変化に伴い
コントロールに比べて僅かに高い値を示した（第３図）
。メディウムの主成分をＢＳＡからラット血清に変えた
ところ、プロリンの作用は大幅に増加し、顕著な脂肪酸
の遊離が検出された。これは肝組織が血清に対して安定
した活性を保つことと、血清中にプロリンによる脂肪酸
の遊離を促進する効果があることを示唆している。以上
の結果は、プロリンが肝組織から脂肪酸を遊離させるこ
とを示している。そして、プＤ ＩＪンによって増加す
る血中の遊離脂肪酸が脂肪体と肝臓から動員されること
が明らかである。(3) Release of fatty acids from the liver Since pro-IJ showed the effect of increasing the free fatty acid level in the blood, the release of fatty acids from the liver was also measured. When we examined the release of fatty acids by adding proline to liver slices in a medium containing BSA as the main component, we found that the release of fatty acids was slightly higher than that of the control over time (Figure 3).
. When the main component of the medium was changed from BSA to rat serum, the effect of proline was significantly increased and significant release of fatty acids was detected. This suggests that liver tissue maintains stable activity against serum and that proline in serum has the effect of promoting the release of fatty acids. The above results indicate that proline liberates fatty acids from liver tissue. It is also clear that free fatty acids in the blood, which increase with DIJ, are mobilized from the fat body and liver.
第１図はプロリン及びスレオニンの遊泳時の血中遊離脂
肪酸値への影響を示す。第２図はプロリンが脂肪体から
脂肪酸の遊離に及ぼす影響を示す。
第３図は肝臓から脂肪酸の遊離に及ぼす影響を示す。
図面の浄書（内容に変更なし）
第１図
クリンン
第２図
第３図
加
■
反応時間 （分）
手続補正書（方式）
２．１２．２１
平成 年 月Figure 1 shows the influence of proline and threonine on blood free fatty acid levels during swimming. Figure 2 shows the effect of proline on the release of fatty acids from fat bodies. Figure 3 shows the effect on the release of fatty acids from the liver. Engraving of drawings (no changes in content) Figure 1 Clean Figure 2 Figure 3 addition ■ Reaction time (minutes) Procedural amendment (method) 2.12.21 1998 Month
Claims (5)
とする脂質代謝調節剤。(1) A lipid metabolism regulator characterized by containing proline and/or threonine.
る血中遊離脂肪酸調節剤。(2) A blood free fatty acid regulating agent containing the lipid metabolism regulating agent according to claim 1 as an active ingredient.
る脂肪体脂肪代謝調節剤。(3) A fat body fat metabolism regulator containing the lipid metabolism regulator according to claim 1 as an active ingredient.
る肝臓脂肪代謝調節剤。(4) A liver fat metabolism regulator containing the lipid metabolism regulator according to claim 1 as an active ingredient.
る食品。(5) A food containing the lipid metabolism regulator according to claim 1 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02240961A JP3096052B2 (en) | 1990-09-11 | 1990-09-11 | Lipid metabolism regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02240961A JP3096052B2 (en) | 1990-09-11 | 1990-09-11 | Lipid metabolism regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04120020A true JPH04120020A (en) | 1992-04-21 |
| JP3096052B2 JP3096052B2 (en) | 2000-10-10 |
Family
ID=17067232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP02240961A Expired - Fee Related JP3096052B2 (en) | 1990-09-11 | 1990-09-11 | Lipid metabolism regulator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3096052B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021671A1 (en) * | 1993-03-24 | 1994-09-29 | Itoham Foods Inc. | Adipocyte differentiation inhibitor peptide and adipocyte differentiation inhibitor containing said peptide as active ingredient |
| WO1997025060A1 (en) * | 1996-01-09 | 1997-07-17 | The Institute Of Physical And Chemical Research | Amino acid compositions |
| JP2004091476A (en) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | Composition for preventing or improving hypertriglyceridemia |
| WO2007049818A1 (en) * | 2005-10-27 | 2007-05-03 | Ajinomoto Co., Inc. | Anti-fatty liver, anti-obesity or hypolipidemic composition |
-
1990
- 1990-09-11 JP JP02240961A patent/JP3096052B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021671A1 (en) * | 1993-03-24 | 1994-09-29 | Itoham Foods Inc. | Adipocyte differentiation inhibitor peptide and adipocyte differentiation inhibitor containing said peptide as active ingredient |
| WO1997025060A1 (en) * | 1996-01-09 | 1997-07-17 | The Institute Of Physical And Chemical Research | Amino acid compositions |
| US6224861B1 (en) | 1996-01-09 | 2001-05-01 | The Institute Of Physical And Chemical Research. | Amino acid composition |
| JP2004091476A (en) * | 2002-07-08 | 2004-03-25 | Taisho Pharmaceut Co Ltd | Composition for preventing or improving hypertriglyceridemia |
| WO2007049818A1 (en) * | 2005-10-27 | 2007-05-03 | Ajinomoto Co., Inc. | Anti-fatty liver, anti-obesity or hypolipidemic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3096052B2 (en) | 2000-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5716926A (en) | Composition of pyruvate and protein and method for increasing protein concentration in a mammal | |
| US5932624A (en) | Vitamin supplement composition | |
| JP2873497B2 (en) | Lipid metabolism regulator | |
| RU2156087C1 (en) | Biologically active addition | |
| IL45912A (en) | Method and compositions containing glycine glucose electrolytes and mineral salts for treating scours | |
| HUE032486T2 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| JP2003500445A (en) | Nutritional supplements | |
| JPH01294631A (en) | Remedy and preventive for diabetic disease, food and drink and table luxury | |
| US20020193341A1 (en) | Vitamin supplement composition | |
| DE3348165C2 (en) | ||
| US20020082299A1 (en) | Method for reducing body weight | |
| JP4812968B2 (en) | Composition for improving attention deficit / hyperactivity disorder | |
| Gaull | Pathogenesis of maple-syrup-urine disease: observations during dietary management and treatment of coma by peritoneal dialysis | |
| JPH04120020A (en) | Lipid metabolism regulation agent | |
| MXPA02003459A (en) | Chromium histidine complexes as nutrient supplements. | |
| JPH0340010B2 (en) | ||
| JP3553992B2 (en) | Metabolic regulator | |
| DE68907386T2 (en) | Use of phytic acid or its salts for the prevention or treatment of liver diseases. | |
| US3658969A (en) | Pharmaceutical compositions useful in citric acid therapy | |
| FR2513122A1 (en) | NEW MEDICINES BASED ON ALGAE EXTRACTS AND CORRESPONDING FORMULATIONS | |
| JPH06256184A (en) | Amino acid preparation for cancer patient | |
| DE60030070T2 (en) | IODIED PROTEINS FOR PREVENTING IODMANDLE STATES | |
| JP3793239B2 (en) | Inhibitor of acetaldehyde toxicity | |
| JPH01275522A (en) | Deodorant agent of body smell and uraroma, food and drink and table luxury of deororant for body smell and uraroma | |
| JPH0995448A (en) | Increase in biotin concentration in blood and biotin-containing beverage or food product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070804 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080804 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |